Tearsheet

Beam Therapeutics (BEAM)

Market Price (12/5/2025): $28.6 | Market Cap: $2.9 Bil
Sector: Health Care | Industry: Biotechnology

Beam Therapeutics (BEAM)

Market Price (12/5/2025): $28.6
Market Cap: $2.9 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -37%	Weak multi-year price returns 2Y Excs Rtn is -47%, 3Y Excs Rtn is -107%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -466 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -837%
1	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.		Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -84%, Rev Chg QQuarterly Revenue Change % is -32%
2			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -607%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -633%
3			Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 65%
4			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%
5			Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -37%
1	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.
2	Weak multi-year price returns 2Y Excs Rtn is -47%, 3Y Excs Rtn is -107%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -466 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -837%
4	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -84%, Rev Chg QQuarterly Revenue Change % is -32%
5	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -607%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -633%
6	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 65%
7	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%
8	Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20%

Valuation, Metrics & Events

	12/5/25	2024	2023	2022	2021
Share Price CYE	$28.60	$24.80	$27.22	$39.11	$79.69
Market Cap CYE ($ Bil)	2.9	2.1	2.2	2.8	5.4
Total Debt ($ Bil)	0.2	0.2	0.2	0.2	0.1
Total Cash ($ Bil)	1.1	0.9	1.2	1.1	1.0
Enterprise Value ($ Bil)	2.0	2.3	2.4	3.0	5.5
Valuation Ratios
P/S TTM	44.2	32.1	5.6	45.0	98.7
P/EBIT TTM	-5.3	-4.9	-11.9	-8.1	-13.0
P/E TTM	-5.9	-5.4	-15.8	-9.5	-13.8
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9	4.4	7.1
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3	-1.2	-2.6
P/E TTM (Sector)	-1.6	-1.5	-1.5	-1.3	-2.8

	12/5/25	2024	2023
Share Price CYE	$28.60	$24.80	$27.22
Market Cap CYE ($ Bil)	2.9	2.1	2.2
Total Debt ($ Bil)	0.2	0.2	0.2
Total Cash ($ Bil)	1.1	0.9	1.2
Enterprise Value ($ Bil)	2.0	2.3	2.4
Valuation Ratios
P/S TTM	44.2	32.1	5.6
P/EBIT TTM	-5.3	-4.9	-11.9
P/E TTM	-5.9	-5.4	-15.8
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3
P/E TTM (Sector)	-1.6	-1.5	-1.5

	BEAM	S&P 500
REVENUE GROWTH	POOR
Rev LTM ($ Bil)	0.1
Rev Chg Q	-32.0%	7.1%
Rev Chg LTM	-84.1%	6.1%
Rev Chg 3Y Avg	77.8%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.5
CFO LTM ($ Bil)	-0.3
Net Inc LTM ($ Bil)	-0.4
Op Mgn LTM	-837.1%	18.8%
CFO/Rev LTM	-607.1%	20.5%
Net Inc Mgn	-744.4%	13.1%
VALUATION	VERY HIGH
P/S	44.2	3.2
P/CFO	-7.3	15.8
P/FCF	-7.0	20.5
P/E	-5.9	23.5
STABILITY	VERY GOOD
Debt/Equity	0.06	0.20
Cash/Assets	0.82	0.07

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Number of Patients Enrolled in BEACON Phase 1/2 Trial of BEAM-101	more than 20	8062024	Link
Number of Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101	6	8062024	Link
Number of Research Programs in Pfizer Collaboration	3	1102022	Link
Number of Research Programs in Apellis Collaboration	6	6302021	Link
Number of Granted U.S. Patents	2	11052024	Link
Number of U.S. Patent Applications	5	3202025	Link
Number of Employees	509	11062025	Link

Upcoming
2/24/2026	Earnings Release	Rev: - EPS: -

BEAM Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

During the approximate time period from August 31, 2025, to December 5, 2025, Beam Therapeutics (BEAM) experienced several key developments that influenced its stock performance. These points highlight significant advancements in its clinical programs, regulatory status, and financial position.

1. Regenerative Medicine Advanced Therapy (RMAT) Designation for BEAM-101. On August 14, 2025, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101 for the treatment of sickle cell disease (SCD). This designation aims to expedite the development and review of promising regenerative medicines for serious or life-threatening diseases with unmet medical needs.

2. Positive Clinical Progress for BEAM-302 in Alpha-1 Antitrypsin Deficiency. Beam Therapeutics reported continued enrollment and dosing progress in the Phase 1/2 trial of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD). As of early November 2025, the trial demonstrated durable correction of the disease-causing mutation, restoration of AAT physiology, and a well-tolerated safety profile with no serious adverse events. Expanded dose exploration in Part A and enrollment initiation in Part B were underway, with updated data and clinical development updates expected in early 2026.

3. Advancement of BEAM-101 with Data Accepted for ASH Presentation. Dosing was completed for 30 sickle cell disease patients, and the first adolescent patient was dosed in the BEACON Phase 1/2 trial of BEAM-101. Updated data from this trial were accepted for presentation at the American Society of Hematology (ASH) Annual Meeting, which took place in December 2025.

4. Initiation of BEAM-103 Healthy Volunteer Trial. By November 4, 2025, Beam Therapeutics initiated dosing of the first subject with BEAM-103, an anti-CD117 monoclonal antibody from its Engineered Stem Cell Antibody Paired Evasion (ESCAPE) platform, in a Phase 1 healthy volunteer clinical trial. This platform is considered to be important for future therapies in sickle cell disease.

5. Strong Cash Position. Beam Therapeutics maintained a robust financial position, reporting $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2025. This strong cash reserve provides a substantial runway, expected to support the company's operating plans into 2028, ensuring funding for ongoing research and development and key clinical milestones.

Show less

Stock Movement Drivers

Fundamental Drivers

The 55.9% change in BEAM stock from 9/4/2025 to 12/4/2025 was primarily driven by a 69.7% change in the company's P/S Multiple.

	9042025	12042025	Change
Stock Price ($)	18.54	28.91	55.93%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	60.27	55.70	-7.58%
P/S Multiple	31.37	53.24	69.68%
Shares Outstanding (Mil)	102.00	102.57	-0.56%
Cumulative Contribution			55.93%

LTM = Last Twelve Months as of date shown

Market Drivers

9/4/2025 to 12/4/2025

	Return	Correlation
BEAM	55.9%
Market (SPY)	5.4%	34.9%
Sector (XLV)	12.0%	29.9%

Fundamental Drivers

The 70.1% change in BEAM stock from 6/5/2025 to 12/4/2025 was primarily driven by a 126.3% change in the company's P/S Multiple.

	6052025	12042025	Change
Stock Price ($)	17.00	28.91	70.06%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	63.58	55.70	-12.39%
P/S Multiple	23.52	53.24	126.31%
Shares Outstanding (Mil)	87.98	102.57	-16.59%
Cumulative Contribution			65.38%

LTM = Last Twelve Months as of date shown

Market Drivers

6/5/2025 to 12/4/2025

	Return	Correlation
BEAM	70.1%
Market (SPY)	15.7%	37.3%
Sector (XLV)	16.2%	28.4%

Fundamental Drivers

The 11.1% change in BEAM stock from 12/4/2024 to 12/4/2025 was primarily driven by a 768.1% change in the company's P/S Multiple.

	12042024	12042025	Change
Stock Price ($)	26.02	28.91	11.11%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	349.64	55.70	-84.07%
P/S Multiple	6.13	53.24	768.05%
Shares Outstanding (Mil)	82.41	102.57	-24.46%
Cumulative Contribution			4.46%

LTM = Last Twelve Months as of date shown

Market Drivers

12/4/2024 to 12/4/2025

	Return	Correlation
BEAM	11.1%
Market (SPY)	13.7%	42.8%
Sector (XLV)	6.3%	36.0%

Fundamental Drivers

The -34.8% change in BEAM stock from 12/5/2022 to 12/4/2025 was primarily driven by a -45.8% change in the company's Shares Outstanding (Mil).

	12052022	12042025	Change
Stock Price ($)	44.37	28.91	-34.84%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	91.95	55.70	-39.42%
P/S Multiple	33.94	53.24	56.84%
Shares Outstanding (Mil)	70.34	102.57	-45.81%
Cumulative Contribution			-48.52%

LTM = Last Twelve Months as of date shown

Market Drivers

12/5/2023 to 12/4/2025

	Return	Correlation
BEAM	2.3%
Market (SPY)	53.3%	40.2%
Sector (XLV)	20.1%	34.3%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BEAM Return	-	-2%	-51%	-30%	-9%	17%	-65%
Peers Return	436%	19%	-45%	23%	11%	-8%	338%
S&P 500 Return	16%	27%	-19%	24%	23%	17%	112%
Monthly Win Rates [3]
BEAM Win Rate	60%	50%	33%	50%	33%	70%
Peers Win Rate	72%	45%	37%	45%	48%	48%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
BEAM Max Drawdown	-	-21%	-63%	-55%	-22%	-41%
Peers Max Drawdown	-24%	-34%	-65%	-42%	-44%	-44%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: SRRK, DNLI, CLDX, TWST, NTLA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/4/2025 (YTD)

How Low Can It Go

Unique Key	Event	BEAM	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-86.8%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	655.2%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-54.4%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	119.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	112 days	148 days

Compare to SRRK, DNLI, CLDX, TWST, NTLA

In The Past

Beam Therapeutics's stock fell -86.8% during the 2022 Inflation Shock from a high on 7/1/2021. A -86.8% loss requires a 655.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Beam Therapeutics (BEAM)

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

AI Generated Analysis | Feedback

Analogies for Beam Therapeutics (BEAM):

It's like CRISPR Therapeutics (CRSP), but using a newer, more precise 'base editing' technology to fix genetic errors.
Think of it as a pioneer in gene editing, similar to how Moderna (MRNA) pioneered mRNA technology, but focused on making precise 'base edits' to DNA for therapeutic purposes.
Similar to the original CRISPR gene-editing companies (e.g., CRISPR Therapeutics), but specializing in a more refined 'base editing' approach that avoids cutting DNA.

AI Generated Analysis | Feedback

BEAM-101: An investigational *ex vivo* base editing program for sickle cell disease and beta-thalassemia, designed to modify hematopoietic stem cells to reduce disease symptoms.
BEAM-201: An investigational *ex vivo* multiplex base edited CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia, engineered to target specific cancer markers.
BEAM-302: An investigational *in vivo* base editing therapy for Glycogen Storage Disease type Ia (GSDIa), delivered to the liver to correct the underlying genetic mutation.

AI Generated Analysis | Feedback

Beam Therapeutics (symbol: BEAM) is a clinical-stage biotechnology company primarily focused on developing precision genetic medicines through base editing. As such, it does not currently have approved products for sale directly to individuals (patients) or healthcare providers.

Instead, Beam Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies that license its proprietary base editing technology or collaborate on research and development programs. Therefore, its major "customers" are other companies within the biopharmaceutical industry.

Major Customer Companies:

Pfizer Inc. (Symbol: PFE)
- In January 2022, Beam Therapeutics announced a significant global collaboration with Pfizer to develop novel in vivo base editing programs for three undisclosed rare diseases. This collaboration includes upfront payments, an equity investment from Pfizer, and potential milestone payments and royalties on future product sales, making Pfizer a key financial partner and "customer" for Beam's technology.
Verve Therapeutics, Inc. (Symbol: VERV)
- Beam has a long-standing strategic collaboration with Verve Therapeutics. Verve utilizes Beam's base editing technology under license for its programs aimed at treating cardiovascular diseases. This collaboration involves milestone payments and royalties to Beam for the use of its technology.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

John Evans, Chief Executive Officer and Board Member

Mr. Evans joined Beam Therapeutics in 2017 as CEO. He previously served as an early employee and member of the leadership team at Agios Pharmaceuticals, where he was Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, he provided strategic and operational leadership for a portfolio of IDH inhibitors and helped initiate and lead a landmark alliance with Celgene, which resulted in over $600 million of funding and investments across multiple research collaborations. He also co-led Agios's expansion into rare genetic diseases. Prior to Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company, and MedImmune. He also served as interim CEO for Prime Medicine.

Terry-Ann Burrell, Chief Financial Officer

Ms. Burrell joined Beam Therapeutics as Chief Financial Officer in 2019. Prior to Beam, she spent 11 years with J.P. Morgan, most recently as a Managing Director in the healthcare investment banking group, where she covered the biotechnology and pharmaceutical industries. During her tenure at J.P. Morgan, she helped execute over $10 billion in equity and equity-linked financings and more than $50 billion in M&A transactions. Earlier in her career, Ms. Burrell worked in equity research at Citigroup, covering specialty pharmaceuticals and generics.

Giuseppe Ciaramella, Ph.D., President

Dr. Ciaramella is the President of Beam Therapeutics. He has over 20 years of drug discovery experience and has held several leadership roles at companies including Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer, and Merck. Before joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics, where he was instrumental in generating some of the first mRNA vaccines to be dosed in humans. He is also a co-founder and CEO of Orbital Therapeutics.

Suzanne Fleming, Senior Vice President, Finance

Ms. Fleming brings more than 25 years of experience in finance leadership roles within the life science industry to Beam Therapeutics. Before joining Beam, she was Senior Vice President, Finance and Treasurer at Epizyme, Inc. Prior to Epizyme, she was Vice President, Finance at Foundation Medicine, where she worked closely with Roche after their purchase of a majority stake in the company. Ms. Fleming also held senior finance positions at Aegerion Pharmaceuticals, AVEO Pharmaceuticals, Transform Pharmaceuticals, and Transkaryotic Therapies.

Manmohan Singh, Ph.D., Chief Technology Officer

Dr. Singh is the Chief Technology Officer at Beam Therapeutics. He has over 24 years of experience in drug discovery and development. Prior to Beam Therapeutics, Dr. Singh was the Global Head of Drug Product Development at Takeda Vaccines, where he oversaw the drug product development of all vaccine programs. His experience also includes roles at Novartis and Chiron Corporation.

AI Generated Analysis | Feedback

Clear emerging threats to Beam Therapeutics (BEAM) include:

    
        The recent FDA approval of exagamglogene autotemcel (exa-cel, Casgevy) developed by CRISPR Therapeutics and Vertex Pharmaceuticals for sickle cell disease and beta-thalassemia. This therapy represents the first-in-class gene-edited treatment for these conditions and directly competes in Beam's lead indication areas. Exa-cel's establishment as an approved treatment sets a high bar and could capture significant market share before Beam's own base-editing therapies (e.g., BEAM-101) are able to reach the market.
    
    
        The advancement and clinical development of prime editing technology by companies like Prime Medicine. Prime editing is another next-generation gene-editing platform, co-invented by Beam's scientific co-founder David Liu, which is capable of making a broader range of precise edits (including all 12 possible base changes, small insertions, and deletions) without requiring double-strand DNA breaks. If prime editing proves to be more versatile, efficient, or safer than base editing in clinical applications, it could pose a significant technological threat, potentially limiting the market or perceived advantages of Beam's base-editing therapies in the long term. Prime Medicine is well-funded and actively advancing its own pipeline, directly competing in therapeutic areas similar to Beam's focus.

AI Generated Analysis | Feedback

Addressable Markets for Beam Therapeutics' Main Products or Services

BEAM-101 (Sickle Cell Disease - SCD):
- The global sickle cell disease treatment market was estimated at USD 2.75 billion in 2023 and is projected to reach USD 7.42 billion by 2030, growing at a CAGR of 15.7% from 2024 to 2030.
- Another estimate for the global market size was USD 2.25 billion in 2022, projected to grow to USD 9.84 billion by 2030, at a CAGR of 20.1% during 2023-2030.
- The U.S. sickle cell disease treatment market was valued at USD 861.84 million in 2024 and is projected to reach approximately USD 3,789.17 million by 2034, with a CAGR of 15.96% from 2025 to 2034.
- North America held the largest revenue share of 36% in the global market in 2024.
BEAM-302 (Alpha-1 Antitrypsin Deficiency - AATD):
- The global Alpha-1 Antitrypsin Deficiency Disease Treatment Market was valued at USD 3.2 billion in 2024 and is projected to reach USD 8,375.42 million by 2032, growing at a CAGR of 12.78%.
- Another source indicates the global market valuation is expected to increase from USD 3.52 billion in 2024 to USD 13.5 billion by 2035, with a CAGR of 12.98% from 2025 to 2035.
- North America dominated the market with a 42% share in 2024.
BEAM-201 (T-cell Acute Lymphoblastic Leukemia - T-ALL/T-cell Lymphoblastic Lymphoma - T-LL):
- The global Acute Lymphoblastic Leukemia (ALL) therapeutics market size was valued at USD 3 billion in 2023 and is predicted to grow at a 6.8% CAGR between 2024 and 2032.
- The global Acute Lymphoblastic Leukemia market size is estimated at USD 3.72 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 7.40% from 2025 to 2033.
- North America is reported to hold the major market share for more than 40% of the global revenue, with a market size of USD 1376.40 million in 2025.
- Another report states the global Acute Lymphoblastic Leukemia Market was valued at USD 3.52 billion in 2024 and is projected to reach USD 6.98 billion by 2034, growing at a CAGR of 7.1% during the forecast period (2025-2034).
- The U.S. acute lymphocytic leukemia therapeutics market size is expected to reach around USD 3.26 billion by 2034 and is growing at a CAGR of 10.5% from 2024 to 2034.
BEAM-301 (Glycogen Storage Disease Type 1a - GSD1a):
- Null

AI Generated Analysis | Feedback

Beam Therapeutics (BEAM) is a pre-commercial biotechnology company whose future revenue growth over the next 2-3 years will primarily be driven by the advancement of its gene editing pipeline and strategic collaborations. Here are the key expected drivers of future revenue growth:

Advancement and Potential Commercialization of BEAM-101 for Sickle Cell Disease (SCD): BEAM-101 is Beam Therapeutics' lead hematology program for severe sickle cell disease. The company has achieved its adult enrollment target in the BEACON Phase 1/2 trial, with updated data expected in mid-2025, and further updates at the ASH meeting in December 2025. BEAM-101 has also received FDA Orphan Drug Designation, which provides benefits such as tax credits for clinical trials, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. Successful clinical outcomes and eventual regulatory approval for BEAM-101 would be a significant revenue driver through potential product sales.
Clinical Progression of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD): BEAM-302, an *in vivo* base editing program for Alpha-1 Antitrypsin Deficiency, is a top priority for Beam Therapeutics and represents the first clinical program to directly correct a disease-causing mutation *in vivo*. The company expects to report initial data from multiple cohorts of the Phase 1/2 study in AATD in early 2026, following positive initial data and advancement to its fourth cohort in Q1 2025. Positive clinical data and progression towards later-stage trials or potential partnerships for BEAM-302 could generate substantial milestone payments and future royalties.
Development of the ESCAPE Platform and BEAM-103: Beam's ESCAPE technology aims to expand the addressable patient population for gene editing by potentially eliminating chemotherapy, which could significantly increase the market for their therapies. The company expects to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103, an ESCAPE monoclonal antibody, by the end of 2025. The success of the ESCAPE platform in enabling non-genotoxic conditioning could open up significant new markets and enhance the revenue potential of Beam's gene-editing programs.
Advancement of BEAM-301 for Glycogen Storage Disease Type Ia (GSD1a): BEAM-301 is Beam's second *in vivo* base editing program to reach clinical testing, with patient dosing in the Phase 1/2 clinical trial expected to commence in early 2025. Successful progression of BEAM-301 through clinical development could contribute to future revenue through milestone payments from collaborations or potential product sales in this rare genetic disorder.
Strategic Collaborations and Licensing Agreements: As a pre-commercial biotechnology company, Beam Therapeutics currently generates revenue primarily through strategic collaborations and licensing agreements. These agreements often include upfront payments, research funding, milestone payments, and potential royalties on future product sales. Beam has secured significant upfront payments from agreements with partners such as Pfizer, Apellis, Verve, and Sana, and continues to engage in strategic initiatives and partnerships to enhance research and development efforts and provide additional funding. Future agreements and the achievement of milestones within existing collaborations will continue to be a crucial revenue driver.

AI Generated Analysis | Feedback

Share Issuance

Beam Therapeutics completed an underwritten public offering in March 2025, generating approximately $500.0 million in gross proceeds through the issuance of 16,151,686 shares of common stock and 1,404,988 pre-funded warrants.
In October 2023, Eli Lilly and Company made a $50 million equity investment in Beam Therapeutics as part of a broader collaboration and license agreement.
As an upfront payment for an acquisition finalized on July 1, 2025, Beam issued 403,128 shares of common stock to the acquired company's shareholders.

Inbound Investments

Beam Therapeutics received an upfront payment of $300 million from Pfizer in February 2022 as part of a four-year research collaboration aimed at developing in vivo base editing programs for rare genetic diseases.
In October 2023, Beam received a $200 million upfront payment and a $50 million equity investment from Eli Lilly and Company, with eligibility for up to an additional $350 million in future development-stage payments.

Outbound Investments

In February 2021, Beam Therapeutics acquired Guide Therapeutics, Inc. for an upfront consideration of $120 million, paid in Beam common stock. GuideTx stockholders are also eligible for up to $320 million in additional milestone payments, payable in Beam common stock.
On July 1, 2025, Beam Therapeutics acquired an early-stage life sciences company, issuing 403,128 shares of its common stock as an upfront payment, with potential future milestone payments of up to $89 million.

Capital Expenditures

Beam Therapeutics reported capital expenditures of approximately $14.18 million over the last 12 months leading up to November 2025.
The company's cash reserves are anticipated to fund its operating expenses and capital expenditure requirements into 2028.
Capital expenditures are primarily focused on advancing key clinical programs such as BEAM-101 for sickle cell disease, the ESCAPE conditioning platform, BEAM-301, and BEAM-302, as well as supporting internal manufacturing capabilities, including its North Carolina facility.

Better Bets than Beam Therapeutics (BEAM)

	BEAM	Better Performance than BEAM
Metric	Value	INDUSTRY: Biotechnology
Rev Chg LTM	-84.1%	AMGN (10.6%), VRTX (10.3%), ABBV (7.4%), REGN (2.9%), GILD (2.8%)
Rev Chg 3Y Avg	77.8%	ARWR (908.8%), CYTK (818.6%), BBIO (727.6%), AXSM (296.0%), RYTM (136.1%)
Op Mgn LTM	-837.1%	GILD (38.3%), REGN (26.7%), AMGN (24.1%), ABBV (24.1%), VRTX (-0.8%)
CFO/Rev LTM	-607.1%	AMGN (36.5%), REGN (35.6%), ABBV (35.0%), GILD (33.2%), VRTX (31.7%)
FCF/Rev LTM	-632.6%	ABBV (33.0%), AMGN (32.1%), GILD (31.5%), VRTX (28.5%), REGN (27.2%)
Total Yield	-16.7%	GILD (8.8%), REGN (8.3%), AMGN (7.9%), VRTX (3.7%), ABBV (3.4%)
P/S	44.7	REGN (4.1), AMGN (4.2), GILD (4.7), ABBV (6.9), VRTX (8.5)
P/Op Inc	-5.3

	BEAM	Better Performance than BEAM
Metric	Value	SECTOR: Health Care
Rev Chg LTM	-84.1%	LLY (36.8%), UNH (10.5%), ABBV (7.4%), JNJ (5.1%), MRK (1.7%)
Rev Chg 3Y Avg	77.8%	ARWR (908.8%), CYTK (818.6%), BBIO (727.6%), AXSM (296.0%), RYTM (136.1%)
Op Mgn LTM	-837.1%	LLY (43.0%), MRK (34.9%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%)
CFO/Rev LTM	-607.1%	ABBV (35.0%), MRK (26.6%), JNJ (26.3%), LLY (20.5%), UNH (4.8%)
FCF/Rev LTM	-632.6%	ABBV (33.0%), MRK (20.3%), JNJ (20.3%), UNH (4.0%), LLY (-0.1%)
Total Yield	-16.7%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/S	44.7	UNH (0.7), MRK (3.3), JNJ (4.8), ABBV (6.9), LLY (12.9)
P/Op Inc	-5.3

	BEAM	Better Performance than BEAM
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	-84.1%	NVDA (71.6%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%), AAPL (6.0%)
Rev Chg 3Y Avg	77.8%	APO (129.8%), IONQ (107.6%), RIVN (103.0%), NVDA (92.0%), SLF (88.9%)
Op Mgn LTM	-837.1%	NVDA (58.1%), MSFT (46.3%), GOOGL (32.2%), AAPL (31.9%), AMZN (11.4%)
CFO/Rev LTM	-607.1%	MSFT (50.0%), NVDA (46.6%), GOOGL (39.3%), AAPL (26.6%), AMZN (18.1%)
FCF/Rev LTM	-632.6%	NVDA (43.6%), MSFT (26.6%), AAPL (23.5%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-16.7%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.3%)
P/S	44.7	AMZN (3.5), GOOGL (7.6), AAPL (9.3), MSFT (13.1), NVDA (23.3)
P/Op Inc	-5.3

		Best Bets In Health Care Sector
	BEAM	RPRX	HALO	DOCS	UTHR	CPRX	HRMY	LGND	ISRG	GMED	MD
What You Pay
P/E	-6.0	19.9	14.4	54.3	14.4	11.1	8.5	71.4	58.1	18.2	8.7
P/EBIT	-5.3	9.6	11.3	55.6	10.9	9.3	6.5	51.9	56.6	17.8	5.9
What You Get
Rev Chg Q	-32.0%	7.9%	22.1%	23.2%	6.8%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%
Rev Chg LTM	-84.1%	3.7%	31.2%	20.2%	13.5%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%
Rev Chg 3Y Avg	77.8%	1.5%	29.0%	17.4%	19.0%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%
FCF/Rev 3Y Avg	-384.9%	115.2%	45.0%	42.7%	34.3%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Beam Therapeutics Stock Jump Looks Great, But How Secure Is That Gain?	Return
2	Why Beam Therapeutics Stock Moved: BEAM Stock Has Lost 70% Since 2021 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S)
3	BEAM Dip Buy Analysis
4	Beam Therapeutics (BEAM) Valuation Ratios Comparison	Financials
5	Beam Therapeutics (BEAM) Stock: 32% of days in last 3 months had 1% or greater fluctuation
6	Beam Therapeutics Total Shareholder Return (TSR): -8.9% in 2024 and -32.2% 3-yr compounded annual returns (below peer average)
7	Beam Therapeutics Stock Up 14% in One Day, Why You Shouldn Not Be Buying The Stock	Buy or Fear
8	Day 5 of Gains Streak for Beam Therapeutics Stock with 26% Return (vs. 35% YTD) [2/19/2025]	Notification
9	Beam Therapeutics (BEAM) Operating Cash Flow Comparison	Financials
10	Beam Therapeutics (BEAM) Net Income Comparison	Financials

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to BEAM. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
USAR	USA Rare Earth	1.8	24.7%	58557.7%
PATH	UiPath	9.9	24.4%	45.4%
ASTS	AST SpaceMobile	17.6	18.2%	244.3%
FLNC	Fluence Energy	3.1	17.6%	47.0%
SAIC	Science Applications International	4.8	16.3%	-7.7%
AEVA	Aeva Technologies	0.9	16.0%	234.3%
AXGN	Axogen	1.5	16.0%	99.4%
SANA	Sana Biotechnology	1.3	15.9%	217.8%
OKLO	Oklo	15.6	15.6%	425.9%
RGTI	Rigetti Computing	9.0	15.4%	97.0%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HOV	Hovnanian Enterprises	0.7	-22.5%	-22.4%
SYM	Symbotic	6.6	-17.4%	155.1%
BBW	Build-A-Bear Workshop	0.6	-15.5%	7.1%
DJCO	Daily Journal	0.6	-11.9%	-22.5%
PVH	PVH	3.7	-11.9%	-26.9%
SNOW	Snowflake	78.7	-11.4%	52.0%
QURE	uniQure	1.2	-10.8%	28.8%
MBX	MBX Biosciences	1.0	-10.0%	65.7%
WLY	John Wiley & Sons	1.8	-8.6%	-18.7%
LUMN	Lumen Technologies	8.7	-8.3%	65.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	7.7	601.0%	-45.7%
HPP	Hudson Pacific Properties	6.1	591.8%	-36.1%
AEVA	Aeva Technologies	0.9	50.8%	234.3%
MPLT	MapLight Therapeutics	0.8	41.2%
USAR	USA Rare Earth	1.8	40.6%	58557.7%
PATH	UiPath	9.9	36.0%	45.4%
EVEX	Eve	1.6	34.4%	-7.4%
TMC	TMC The Metals	2.9	33.8%	596.4%
TE	T1 Energy	0.8	33.1%
INDI	Indie Semiconductor	0.9	32.1%	13.8%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.0	-52.7%	-69.4%
CTEV	Claritev	0.6	-32.7%
SYM	Symbotic	6.6	-30.7%	155.1%
FULC	Fulcrum Therapeutics	0.5	-22.6%	86.4%
HOV	Hovnanian Enterprises	0.7	-22.0%	-22.4%
VTYX	Ventyx Biosciences	0.6	-19.9%	265.3%
SIG	Signet Jewelers	3.5	-17.8%	7.2%
CMCL	Caledonia Mining	0.5	-17.8%	175.7%
QURE	uniQure	1.2	-17.7%	28.8%
URGN	UroGen Pharma	1.2	-17.5%	128.0%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
LXP	LXP Industrial Trust	2.8	406.1%	25.7%
OLMA	Olema Pharmaceuticals	2.4	237.1%	374.1%
COGT	Cogent Biosciences	5.4	178.2%	404.0%
CDTX	Cidara Therapeutics	5.9	119.6%	720.3%
SGML	Sigma Lithium	1.1	113.2%	-11.1%
IRWD	Ironwood Pharmaceuticals	0.6	99.5%	-15.8%
ALMS	Alumis	0.6	82.4%	5.6%
NPCE	NeuroPace	0.6	80.5%	51.7%
BW	Babcock & Wilcox Enterprises	0.7	80.5%	311.6%
CBLL	CeriBell	0.7	75.4%	-26.0%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
CCOI	Cogent Communications	0.9	-53.0%	-74.0%
UP	Wheels Up Experience	0.5	-48.0%	-60.0%
TLRY	Tilray Brands	7.7	-41.8%	-45.7%
AMSC	American Superconductor	1.4	-41.4%	34.0%
CTEV	Claritev	0.6	-41.2%
BTDR	Bitdeer Technologies	2.5	-40.7%	-41.6%
FRMI	Fermi	11.1	-40.2%
JANX	Janux Therapeutics	1.0	-39.3%	-69.4%
ARDT	Ardent Health	1.2	-39.1%	-48.1%
SMR	NuScale Power	3.4	-35.9%	27.4%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
USAR	USA Rare Earth	1.8	24.7%	58557.7%
PATH	UiPath	9.9	24.4%	45.4%
ASTS	AST SpaceMobile	17.6	18.2%	244.3%
FLNC	Fluence Energy	3.1	17.6%	47.0%
SAIC	Science Applications International	4.8	16.3%	-7.7%
AEVA	Aeva Technologies	0.9	16.0%	234.3%
AXGN	Axogen	1.5	16.0%	99.4%
SANA	Sana Biotechnology	1.3	15.9%	217.8%
OKLO	Oklo	15.6	15.6%	425.9%
RGTI	Rigetti Computing	9.0	15.4%	97.0%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HOV	Hovnanian Enterprises	0.7	-22.5%	-22.4%
SYM	Symbotic	6.6	-17.4%	155.1%
BBW	Build-A-Bear Workshop	0.6	-15.5%	7.1%
DJCO	Daily Journal	0.6	-11.9%	-22.5%
PVH	PVH	3.7	-11.9%	-26.9%
SNOW	Snowflake	78.7	-11.4%	52.0%
QURE	uniQure	1.2	-10.8%	28.8%
MBX	MBX Biosciences	1.0	-10.0%	65.7%
WLY	John Wiley & Sons	1.8	-8.6%	-18.7%
LUMN	Lumen Technologies	8.7	-8.3%	65.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	7.7	601.0%	-45.7%
HPP	Hudson Pacific Properties	6.1	591.8%	-36.1%
AEVA	Aeva Technologies	0.9	50.8%	234.3%
MPLT	MapLight Therapeutics	0.8	41.2%
USAR	USA Rare Earth	1.8	40.6%	58557.7%
PATH	UiPath	9.9	36.0%	45.4%
EVEX	Eve	1.6	34.4%	-7.4%
TMC	TMC The Metals	2.9	33.8%	596.4%
TE	T1 Energy	0.8	33.1%
INDI	Indie Semiconductor	0.9	32.1%	13.8%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.0	-52.7%	-69.4%
CTEV	Claritev	0.6	-32.7%
SYM	Symbotic	6.6	-30.7%	155.1%
FULC	Fulcrum Therapeutics	0.5	-22.6%	86.4%
HOV	Hovnanian Enterprises	0.7	-22.0%	-22.4%
VTYX	Ventyx Biosciences	0.6	-19.9%	265.3%
SIG	Signet Jewelers	3.5	-17.8%	7.2%
CMCL	Caledonia Mining	0.5	-17.8%	175.7%
QURE	uniQure	1.2	-17.7%	28.8%
URGN	UroGen Pharma	1.2	-17.5%	128.0%

Peer Comparisons for Beam Therapeutics

Peers to compare with:

Financials

	BEAM	SRRK	DNLI	CLDX	TWST	NTLA	Median
Name	Beam The.	Scholar .	Denali T.	Celldex .	Twist Bi.	Intellia.
Mkt Price	28.91	45.20	20.11	29.60	32.81	9.74	29.26
Mkt Cap	3.0	5.1	3.5	2.0	2.0	1.1	2.5
Rev LTM	56	0	0	6	362	58	31
Op Inc LTM	-466	-323	-548	-235	-142	-479	-395
FCF LTM	-352	-258	-412	-188	-69	-413	-305
FCF 3Y Avg	-297	-186	-378	-142	-103	-394	-241
CFO LTM	-338	-258	-398	-186	-51	-411	-298
CFO 3Y Avg	-276	-186	-364	-140	-81	-386	-231

Growth & Margins

	BEAM	SRRK	DNLI	CLDX	TWST	NTLA	Median
Name	Beam The.	Scholar .	Denali T.	Celldex .	Twist Bi.	Intellia.
Rev Chg LTM	-84.1%	-	-	-30.2%	22.7%	33.5%	-3.8%
Rev Chg 3Y Avg	77.8%	-	-	139.9%	25.3%	5.8%	51.5%
Rev Chg Q	-32.0%	-	-	-70.8%	17.9%	51.3%	-7.1%
QoQ Delta Rev Chg LTM	-7.6%	-	-	-23.4%	4.2%	8.8%	-1.7%
Op Mgn LTM	-837.1%	-	-	-4,053.7%	-39.3%	-832.2%	-834.6%
Op Mgn 3Y Avg	-459.3%	-	-	-3,248.6%	-65.1%	-1,006.0%	-732.6%
QoQ Delta Op Mgn LTM	-97.2%	-	-	-1,180.2%	5.6%	136.5%	-45.8%
CFO/Rev LTM	-607.1%	-	-	-3,215.2%	-14.1%	-713.8%	-660.5%
CFO/Rev 3Y Avg	-359.8%	-	-	-2,713.8%	-30.0%	-765.6%	-562.7%
FCF/Rev LTM	-632.6%	-	-	-3,254.8%	-19.0%	-717.3%	-674.9%
FCF/Rev 3Y Avg	-384.9%	-	-	-2,749.0%	-38.1%	-782.2%	-583.6%

Valuation

	BEAM	SRRK	DNLI	CLDX	TWST	NTLA	Median
Name	Beam The.	Scholar .	Denali T.	Celldex .	Twist Bi.	Intellia.
Mkt Cap	3.0	5.1	3.5	2.0	2.0	1.1	2.5
P/S	44.7	-	-	233.3	6.1	33.1	38.9
P/EBIT	-5.3	-12.5	-4.6	-5.8	-13.1	-4.0	-5.5
P/E	-6.0	-12.6	-5.0	-6.8	-25.9	-4.3	-6.4
P/CFO	-7.4	-15.5	-6.3	-7.3	-43.2	-4.6	-7.3
Total Yield	-16.7%	-7.9%	-19.9%	-14.8%	-3.9%	-23.4%	-15.7%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	-14.0%	-16.4%	-12.1%	-8.7%	-6.6%	-17.9%	-13.0%
D/E	0.1	0.0	0.0	0.0	0.0	0.1	0.0
Net D/E	-0.4	-0.1	-0.3	-0.5	-0.1	-0.2	-0.3

Returns

	BEAM	SRRK	DNLI	CLDX	TWST	NTLA	Median
Name	Beam The.	Scholar .	Denali T.	Celldex .	Twist Bi.	Intellia.
1M Rtn	27.1%	61.1%	34.8%	24.1%	9.1%	-20.2%	25.6%
3M Rtn	55.9%	39.3%	36.0%	29.9%	28.0%	-16.2%	33.0%
6M Rtn	70.1%	32.0%	41.4%	51.6%	8.2%	28.5%	36.7%
12M Rtn	11.1%	13.7%	-15.1%	11.4%	-37.4%	-32.8%	-2.0%
3Y Rtn	-34.8%	489.3%	-35.0%	-19.3%	18.3%	-76.8%	-27.1%
1M Excs Rtn	25.9%	59.9%	33.5%	22.8%	7.9%	-21.4%	24.4%
3M Excs Rtn	32.7%	38.1%	24.5%	23.6%	21.6%	-25.0%	24.1%
6M Excs Rtn	54.6%	16.5%	26.0%	36.1%	-7.3%	13.0%	21.2%
12M Excs Rtn	-11.2%	5.7%	-34.9%	-4.7%	-48.2%	-51.5%	-23.1%
3Y Excs Rtn	-107.0%	422.3%	-106.6%	-86.9%	-39.9%	-153.0%	-96.7%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/4/2025	2/25/2025	2/27/2024	2/28/2023	2/28/2022	3/15/2021	3/30/2020
Key Financials
Total Revenue	56	64	378	61	52	0	0
EBITDA	-435	-384	-147	-316	-385	-128	-72
Operating Income	-466	-416	-176	-338	-392	-133	-75
Net Income	-415	-377	-133	-289	-371	-195	-78
EPS	-4.43	-4.58	-1.72	-4.13	-5.77	-4.19	-2.01
Growth Rates
Total Revenue Growth	-84.1%	-83.2%	520.0%	17.5%	215916.7%	33.3%	∞%
EBITDA Growth	-187.2%	-161.3%	53.5%	18.0%	-200.7%	-78.7%	38.3%
Operating Income Growth	-155.3%	-135.5%	47.9%	13.8%	-195.6%	-76.7%	-64.3%
Net Income Growth	-188.8%	-184.3%	54.2%	22.0%	-90.5%	-148.4%	32.0%
Margins
EBITDA Margin	-780.1%	-604.5%	-38.9%	-518.6%	-742.6%	-533437.5%	-398061.1%
Operating Income Margin	-837.1%	-654.3%	-46.7%	-555.6%	-757.0%	-553166.7%	-417522.2%
Net Income Margin	-744.4%	-593.1%	-35.1%	-474.5%	-714.9%	-810800.0%	-435144.4%
Cash & Debt
Total Cash	1,075	851	1,190	1,078	966	300	92
Total Debt	151	161	173	179	142	100	26
Net Debt / (Cash)	-924	-689	-1,017	-899	-823	-199	-66
Cash Flows
Net Cash from Operations	-338	-347	-149	23	-66	-96	-72
Free Cash from Operations	-352	-356	-183	-26	-113	-112	-85
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/4/2025	8/5/2025	5/6/2025	2/25/2025	11/5/2024	8/6/2024	5/7/2024	2/27/2024	11/8/2023	8/8/2023	5/10/2023	2/28/2023
Key Financials Quarterly
Total Revenue	10	8	7	30	14	12	7	316	17	20	24	20
Ebitda	-121	-115	-114	-85	-101	-99	-99	148	-103	-97	-94	-77
Operating Income	-127	-120	-119	-100	-107	-105	-104	133	-108	-102	-99	-89
Net Income	-113	-102	-109	-90	-97	-91	-99	143	-96	-83	-96	-38
EPS	-1.10	-1.00	-1.24	-1.09	-1.17	-1.11	-1.21	1.77	-1.22	-1.08	-1.33	-0.54
Key Financials TTM
Total Revenue TTM	56	60	64	64	350	353	361	378	82	80	77	61
Ebitda TTM	-435	-414	-399	-384	-151	-153	-151	-147	-371	-356	-337	-316
Operating Income TTM	-466	-446	-431	-416	-183	-184	-182	-176	-398	-381	-361	-338
Net Income TTM	-415	-399	-387	-377	-144	-143	-135	-133	-314	-327	-316	-289
Growth Rates Quarterly
Total Revenue Growth	-32.0%	-28.1%	0.8%	-90.5%	-17.0%	-41.5%	-69.4%	1478.0%	8.8%	20.8%	187.1%	-60.8%
EBITDA Growth	-20.0%	-15.4%	-15.3%	-157.5%	2.0%	-2.0%	-4.7%	292.8%	-17.4%	-23.9%	-29.3%	-25.9%
Operating Income Growth	-19.1%	-14.5%	-14.6%	-175.3%	1.6%	-2.7%	-5.3%	249.3%	-18.6%	-24.6%	-29.8%	-40.2%
Net Income Growth	-16.6%	-12.3%	-10.7%	-163.3%	-0.6%	-10.0%	-2.3%	472.4%	12.3%	-15.0%	-39.4%	40.7%
Margins Quarterly
EBITDA Margin	-1250.3%	-1353.8%	-1522.9%	-282.5%	-708.0%	-843.7%	-1332.0%	46.7%	-599.5%	-483.9%	-389.5%	-382.3%
Operating Income Margin	-1307.6%	-1419.2%	-1596.9%	-332.7%	-746.4%	-891.1%	-1405.3%	42.0%	-629.7%	-507.8%	-408.7%	-444.1%
Net Income Margin	-1162.4%	-1208.3%	-1462.8%	-300.5%	-677.5%	-773.5%	-1331.6%	45.2%	-558.9%	-411.5%	-398.5%	-191.4%
Cash & Debt
Total Cash	1,075	1,150	1,220	851	926	1,008	1,095	1,190	1,015	1,073	1,059	1,078
Total Debt	151	155	158	161	162	165	168	173	173	175	176	179
Net Debt / (Cash)	-924	-996	-1,062	-689	-764	-843	-926	-1,017	-843	-898	-883	-899
Cash Flows Quarterly
FCF from Operations	-81	-76	-104	-76	-88	-83	-100	135	-90	-85	-110	-69
Cash Flows TTM
FCF from Operations TTM	-338	-345	-351	-347	-136	-137	-139	-149	-353	-338	-306	23
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-26.2%	-26.3%	-27.5%	-24.8%	-28.3%	-30.2%	-32.7%	45.6%	-34.1%	-35.5%	-38.3%	-39.9%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-24.1%	-24.4%	-24.8%	-25.8%	-12.1%	-13.3%	-14.2%	-15.3%	-31.4%	-33.1%	-35.0%	-38.0%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Single Segment	378	61	52	0	0
Total	378	61	52	0	0

Price Behavior

Price Behavior

Market Price	$28.91
Market Cap ($ Bil)	3.0
First Trading Date	02/06/2020
Distance from 52W High	-15.2%
	50 Days	200 Days
DMA Price	$24.74	$21.14
DMA Trend	down	up
Distance from DMA	16.9%	36.8%
	3M	1YR
Volatility	83.9%	77.1%
Downside Capture	192.28	201.61
Upside Capture	359.99	187.68
Correlation (SPY)	34.9%	43.0%

BEAM Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.75	2.18	2.36	2.44	1.65	1.85
Up Beta	3.42	2.22	2.57	2.08	1.27	1.38
Down Beta	1.59	1.51	2.16	2.07	1.91	2.00
Up Capture	180%	256%	413%	417%	247%	815%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	10	20	30	60	122	355
Down Capture	105%	222%	152%	212%	141%	111%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	9	21	32	64	125	389

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of BEAM With Other Asset Classes (Last 1Y)
	BEAM	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	5.6%	5.8%	14.6%	57.6%	4.7%	-5.6%	-3.5%
Annualized Volatility	77.2%	17.3%	19.6%	19.4%	15.9%	17.8%	35.7%
Sharpe Ratio	0.40	0.16	0.57	2.22	0.10	-0.47	0.03
Correlation With Other Assets		35.8%	42.6%	4.9%	12.1%	32.0%	29.0%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of BEAM With Other Asset Classes (Last 5Y)
	BEAM	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-8.3%	8.9%	15.1%	18.0%	11.7%	4.8%	40.5%
Annualized Volatility	78.3%	14.4%	17.1%	15.5%	18.8%	19.0%	49.0%
Sharpe Ratio	0.23	0.43	0.71	0.93	0.51	0.17	0.68
Correlation With Other Assets		32.4%	44.3%	6.2%	7.4%	36.7%	28.4%

Based On 10-Year Data

		Comparison of BEAM With Other Asset Classes (Last 10Y)
	BEAM	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	7.7%	9.7%	14.5%	14.2%	5.7%	5.3%	76.1%
Annualized Volatility	80.8%	16.7%	18.0%	14.8%	17.7%	20.9%	55.9%
Sharpe Ratio	0.45	0.48	0.69	0.79	0.25	0.23	0.94
Correlation With Other Assets		31.2%	39.8%	8.0%	12.0%	32.6%	26.8%

Short Interest

Short Interest: As Of Date	11142025
Short Interest: Shares Quantity	20,550,660
Short Interest: % Change Since 10312025	3.7%
Average Daily Volume	2,374,359
Days-to-Cover Short Interest	8.66
Basic Shares Quantity	102,570,801
Short % of Basic Shares	20.0%

Returns Analyses

	Title
0	Beam Therapeutics Stock Jump Looks Great, But How Secure Is That Gain?

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11042025	10-Q 9/30/2025
6302025	8052025	10-Q 6/30/2025
3312025	5062025	10-Q 3/31/2025
12312024	2252025	10-K 12/31/2024
9302024	11052024	10-Q 9/30/2024
6302024	8062024	10-Q 6/30/2024
3312024	5072024	10-Q 3/31/2024
12312023	2272024	10-K 12/31/2023
9302023	11082023	10-Q 9/30/2023
6302023	8082023	10-Q 6/30/2023
3312023	5102023	10-Q 3/31/2023
12312022	2282023	10-K 12/31/2022
9302022	11072022	10-Q 9/30/2022
6302022	8092022	10-Q 6/30/2022
3312022	5092022	10-Q 3/31/2022
12312021	2282022	10-K 12/31/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Beam Therapeutics (BEAM)

Market Price (12/5/2025): $28.6 | Market Cap: $2.9 BilSector: Health Care | Industry: Biotechnology

Beam Therapeutics (BEAM)

Market Price (12/5/2025): $28.6Market Cap: $2.9 BilSector: Health CareIndustry: Biotechnology

Valuation, Metrics & Events

BEAM Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Beam Therapeutics (BEAM)

Major Customer Companies:

Addressable Markets for Beam Therapeutics' Main Products or Services

Interactive Breakdown

Better Bets than Beam Therapeutics (BEAM)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Beam Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/5/2025): $28.6 | Market Cap: $2.9 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (12/5/2025): $28.6
Market Cap: $2.9 Bil
Sector: Health Care
Industry: Biotechnology